We further found that there was a negative correlation between RNASET2 and FBXO6 protein in clinical ovarian cancer samples, suggesting that blocking the interaction between FBXO6 and RNASET2 might be a novel anti-ovarian cancer strategy. The gene discussed is FBXO6; the disease is ovarian carcinoma.